港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批有望助推销售额提升

智通财经04-09

智通财经APP获悉，君实生物(01877)涨超6%，截至发稿，涨6.65%，报10.58港元，成交额891.6万港元。消息面上，君实生物日前公布，由公司自主研发的特瑞普利单抗联合阿昔替尼一线治疗中高危不可切除或转移性肾细胞癌患者的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国获批的第八项适应症，也是我国首个获批的肾癌免疫疗法。方正证券指出，特瑞普利肾癌独家...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426185517?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-09 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426185517","market":"sh","top_or_hot":-1,"title":"港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批 有望助推销售额提升","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，君实生物(01877)涨超6%，截至发稿，涨6.65%，报10.58港元，成交额891.6万港元。消息面上，君实生物日前公布，由公司自主研发的特瑞普利单抗联合阿昔替尼一线治疗中高危不可切除或转移性肾细胞癌患者的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国获批的第八项适应症，也是我国首个获批的肾癌免疫疗法。方正证券指出，特瑞普利肾癌独家...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1099817.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批 有望助推销售额提升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批 有望助推销售额提升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-09 11:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1099817.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，君实生物(01877)涨超6%，截至发稿，涨6.65%，报10.58港元，成交额891.6万港元。消息面上，君实生物日前公布，由公司自主研发的特瑞普利单抗联合阿昔替尼一线治疗中高危不可切除或转移性肾细胞癌患者的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国获批的第八项适应症，也是我国首个获批的肾癌免疫疗法。方正证券指出，特瑞普利肾癌独家...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1099817.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07226","symbol_name":"XL二南方恒科","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1099817.html","article_id":"2426185517","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426185517","pubTimestamp":1712632383,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"方正证券指出，特瑞普利肾癌独家适应症上市，有望推动销售额进一步增长。2023年，特瑞普利单抗销售收入约9亿元，同比增长约25%。此次肾癌独家适应症的获批，将有助于其销售额进一步提升。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"07226":"XL二南方恒科","BK4588":"碎股","BK1515":"抗疫概念","BK1161":"生物科技","BK4585":"ETF&股票定投概念","YINN":"三倍做多富时中国ETF-Direxion","YANG":"三倍做空富时中国ETF-Direxion","01877":"君实生物","BK1583":"高瓴概念"},"translate_title":"Hong Kong stocks changed Junshi Bio (01877) rose by more than 6%. The approval of Tripley kidney cancer indications is expected to boost sales","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1,"07226":1,"YANG":1,"YINN":1},"content_text":"智通财经APP获悉，君实生物(01877)涨超6%，截至发稿，涨6.65%，报10.58港元，成交额891.6万港元。消息面上，君实生物日前公布，由公司自主研发的特瑞普利单抗联合阿昔替尼一线治疗中高危不可切除或转移性肾细胞癌患者的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国获批的第八项适应症，也是我国首个获批的肾癌免疫疗法。方正证券指出，特瑞普利肾癌独家适应症上市，有望推动销售额进一步增长。2023年，特瑞普利单抗销售收入约9亿元，同比增长约25%。该行根据肾癌新发人数、mPFS，PD-1渗透率以及特瑞普利市占率进行测算，预计特瑞普利1L治疗肾细胞癌销售峰值可达4.57亿元人民币。此次肾癌独家适应症的获批，将有助于其销售额进一步提升。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426185517"}

港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批 有望助推销售额提升

精彩评论

港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批有望助推销售额提升